vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.
CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $83.5M, roughly 1.6× BillionToOne, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 6.8%, a 75.7% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 55.1%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
BLLN vs CTRE — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $134.9M |
| Net Profit | $5.7M | $111.3M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 82.5% |
| Revenue YoY | 117.4% | 55.1% |
| Net Profit YoY | 138.3% | 113.5% |
| EPS (diluted) | $0.10 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $134.9M | ||
| Q3 25 | $83.5M | $132.4M | ||
| Q2 25 | — | $112.5M | ||
| Q1 25 | — | $96.6M | ||
| Q4 24 | — | $86.9M | ||
| Q3 24 | $38.4M | $77.4M | ||
| Q2 24 | — | $68.9M | ||
| Q1 24 | — | $63.1M |
| Q4 25 | — | $111.3M | ||
| Q3 25 | $5.7M | $74.9M | ||
| Q2 25 | — | $68.5M | ||
| Q1 25 | — | $65.8M | ||
| Q4 24 | — | $52.1M | ||
| Q3 24 | $-14.9M | $33.4M | ||
| Q2 24 | — | $10.8M | ||
| Q1 24 | — | $28.7M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.5% | 58.1% | ||
| Q2 25 | — | 61.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -32.9% | 43.0% | ||
| Q2 24 | — | 15.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 82.5% | ||
| Q3 25 | 6.8% | 56.6% | ||
| Q2 25 | — | 60.9% | ||
| Q1 25 | — | 68.1% | ||
| Q4 24 | — | 60.0% | ||
| Q3 24 | -38.8% | 43.2% | ||
| Q2 24 | — | 15.6% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | — | $0.52 | ||
| Q3 25 | $0.10 | $0.35 | ||
| Q2 25 | — | $0.35 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.30 | ||
| Q3 24 | $-1.47 | $0.21 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $198.0M |
| Total DebtLower is stronger | $55.0M | $894.2M |
| Stockholders' EquityBook value | $-239.5M | $4.0B |
| Total Assets | $327.5M | $5.1B |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $198.0M | ||
| Q3 25 | $195.2M | $712.5M | ||
| Q2 25 | — | $306.1M | ||
| Q1 25 | — | $26.5M | ||
| Q4 24 | — | $213.8M | ||
| Q3 24 | — | $377.1M | ||
| Q2 24 | — | $495.1M | ||
| Q1 24 | — | $451.2M |
| Q4 25 | — | $894.2M | ||
| Q3 25 | $55.0M | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M | ||
| Q1 24 | — | $595.9M |
| Q4 25 | — | $4.0B | ||
| Q3 25 | $-239.5M | $4.0B | ||
| Q2 25 | — | $3.3B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $-242.9M | $2.4B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | — | $5.1B | ||
| Q3 25 | $327.5M | $5.1B | ||
| Q2 25 | — | $4.7B | ||
| Q1 25 | — | $3.9B | ||
| Q4 24 | — | $3.4B | ||
| Q3 24 | — | $2.9B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.3B |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $394.0M |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | 3.54× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $394.0M | ||
| Q3 25 | $13.8M | $100.9M | ||
| Q2 25 | — | $100.8M | ||
| Q1 25 | — | $71.4M | ||
| Q4 24 | — | $244.3M | ||
| Q3 24 | — | $67.2M | ||
| Q2 24 | — | $53.0M | ||
| Q1 24 | — | $48.8M |
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3.54× | ||
| Q3 25 | 2.42× | 1.35× | ||
| Q2 25 | — | 1.47× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 4.68× | ||
| Q3 24 | — | 2.01× | ||
| Q2 24 | — | 4.92× | ||
| Q1 24 | — | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CTRE
Segment breakdown not available.
